The relevance of the mutation category to disease course and outcome of JMML remains controversial [2–4, 22], but higher CREBBP methylation in JMML with PTPN11 mutation or NF1 is consistent with the prevailing opinion that these subgroups are more aggressive. Here, CREBBP is linked to juvenile myelomonocytic leukemia.